References
- Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23–43
- Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv 2010;7:977–92
- Arbiser JL, Li XC, Hossain CF, et al. Naturally occurring proteasome inhibitors from mate tea (Ilex paraguayensis) serve as models for topical proteasome inhibitors. J Invest Dermatol 2005;125:207–12
- Henry L, Le Gallic L, Garcin G, et al. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin. Br J Dermatol 2011;165:311–20
- Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 2010;398:165–78
- Goebel AS, Neubert RH, Wohlrab J. Dermal targeting of tacrolimus using colloidal carrier systems. Int J Pharm 2011;404:159–68
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9:165–9
- Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367–71
- Goodman WA, Levine AD, Massari JV, et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009;183:3170–6
- BASF. Irganox 1010, Technical Information [online]. Basel, Switzerland; 2010. Available from: http://www.telko.com/files/images/telko/ru/basf/termostabilizator/irganox_1010_tds.pdf [last accessed 9 Sep 2015]
- Notman R, den Otter WK, Noro MG, et al. The permeability enhancing mechanism of DMSO in ceramide bilayers simulated by molecular dynamics. Biophys J 2007;93:2056–68
- Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009;143:238–45
- Kolli CS, Banga AK. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res 2008;25:104–13
- Duan D, Moeckly C, Gysbers J, et al. Enhanced delivery of topically-applied formulations following skin pre-treatment with a hand-applied, plastic microneedle array. Curr Drug Deliv 2011;8:557–65
- Weniger BG, Glenn GM. Cutaneous vaccination: antigen delivery into or onto the skin. Vaccine 2013;31:3389–91
- Zhang W, Gao J, Zhu Q, et al. Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. Int J Pharm 2010;402:205–12
- Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Skin irritation and sensitization testing of generic transdermal drug products. Maryland: FDA; 1999:1–11
- Tan CH, Rasool S, Johnston GA. Contact dermatitis: allergic and irritant. Clin Dermatol 2014;32:116–24
- Kandarova H, Klausner M, Kubilus J, et al., (eds). Update on validation status and industry utilization of normal human 3D (NHU-3D) animal alternative models. Presented at 8th World Congress on Alternative and Animal Use; 2011; Montreal, Canada
- Fahr A, van Hoogevest P, May S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251–65
- Elango T, Dayalan H, Subramanian S, et al. Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. Clin Chim Acta 2012;413:1652–6